Effect of Dapagliflozin on IAH in T1DM
- Sponsor
- Radboud University Medical Center
- Study ID
- NCT03556033
- Phase
- PHASE2
- Status
- Completed
Conditions
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Hypoglycemia Unawareness
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin — DRUG8 weeks treatment with dapagliflozin on top of insulin treatment
- Placebo oral capsule — DRUG8 weeks treatment with placebo capsules on top of insulin treatment
Study Details
Approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect hypoglycaemia, a condition referred to as impaired awareness of hypoglycaemia (IAH) that causes a six-fold higher risk of severe, potentially hazardous, hypoglycaemia. IAH is usually the end-result of a process of habituation to recurrent hypoglycaemia that is potentially reversible. Treatment with sodium glucose cotransporter (SGLT)-2 inhibitors (SGLT-2i) in addition to insulin therapy may decrease the incidence of hypoglycaemia in patients with type 1 diabetes. This study will test the hypothesis that treatment with the SGLT-2 inhibitor, dapagliflozin, added to basal-bolus insulin therapy will improve awareness of hypoglycaemia in patients with type 1 diabetes and IAH. In a randomized doubleblind placebo-controlled cross-over trial, patients will be treated for 8 weeks with dapagliflozin (or placebo), after which hypoglycemic symptoms and counterregulatory hormone responses will be examined during a hyperinsulinemic hypoglycemic glucose clamp study.
Key Dates
- Start date
- Nov 23, 2018
- Status verified
- Sep 2019
- Primary completion
- Dec 20, 2019
- Completion
- Dec 20, 2019
Study Design
- Enrollment
- 15 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Active Comparator: DapagliflozinDapagliflozin 10 mg capsule once daily for 8 weeks
- Placebo Comparator: Placebo oral capsulePlacebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
Primary Outcome Measure
Symptom score in response to insulin-induced hypoglycaemia [ Time Frame: 45 minutes ]
Related Studies
- Diagnosing and Treating Low Blood Sugar LevelsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- TrialNet Pathway to Prevention of T1DRecruiting · University of South Florida · Orange, California
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryEARLY_PHASE1 · Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
- Islet Transplantation in Type 1 Diabetic Kidney AllograftPHASE2 · Recruiting · University of Chicago · Chicago, Illinois